Skip to main content

Table 18 The cost-effectiveness analysis in the 24-month period (the reversion rate)

From: The cost-effectiveness analysis of JinQi Jiangtang tablets for the treatment on prediabetes: a randomized, double-blind, placebo-controlled, multicenter design

Group

C (yuan)

E (%)

C/E

ΔC/ΔE

The treatment group

44911142.2

41.1

995812.5

 

The control group

40740835.2

30

1358027.8

276179.3